Pure Global
NCT06382987

A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect)

Registry of Psoriasis Health Outcomes: A Longitudinal Real-world Collaboration (RePhlect) - A Real-World, Prospective, Observational Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan
Bristol-Myers Squibb·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Plaque Psoriasis
Drug/Device/Intervention
Deucravacitinib
Study type
Observational
Intervention type
drug
Sponsor & location
Primary sponsor
Bristol-Myers Squibb
Location
Minato-ku,Fukuoka, Japan
Timeline & enrollment
Phase
N/A
Start date
Jan 22, 2024
End date
Dec 31, 2029
Enrollment
600 participants
Primary outcome

Change in percent Body Surface Area (BSA) involved affected by plaque psoriasis from baseline to follow up in participants treated with deucravacitinib.,Number of participants who achieved Physician's Global Assessment (PGA) of 0/1 from baseline to follow-up,Number of participants who achieved Absolute Psoriasis Area and Severity Index (aPASI) of ≤2 from baseline to follow-up,Number of participants who achieved Dermatology Life Quality Index (DLQI) of 0 /1 from baseline to follow-up,Participant duration of treatment (time difference between date of treatment initiation to date of discontinuation)

Summary

This is a prospective, observational, real-world study of adult participants in Japan with
 physician-reported diagnosis of plaque psoriasis treated with deucravacitinib or apremilast.

ICD-10 classifications
PsoriasisLarge plaque parapsoriasisOther psoriasisSmall plaque parapsoriasisArthropathic psoriasis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06382987
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06382987 through Pure Global AI's free database. This phase not specified trial is sponsored by Bristol-Myers Squibb and is currently Recruiting. The study focuses on Plaque Psoriasis. Target enrollment is 600 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.